U.S. FDA grants full approval to Pfizer-BioNTech COVID-19 vaccine

While shot has been authorized for emergency use since December, Pfizer jab is first to receive full FDA approval, in a move health officials hope will convince more people to get vaccinated

Reuters|
The U.S. Food and Drug Administration on Monday gave full approval to the COVID-19 vaccine made by Pfizer Inc and German partner BioNTech SE for use in people over the age of 16, in the first such approval of a COVID-19 shot.
  • Follow Ynetnews on Facebook and Twitter

  • The vaccine has been authorized for emergency use since December and more than 204 million people in the United States have received it, based on Sunday's data. But none of the three authorized COVID-19 vaccines had previously received full FDA approval.
    2 View gallery
    חיסוני קורונה בתל אביב
    חיסוני קורונה בתל אביב
    The Pfizer COVID vaccine being prepared for administration
    (Photo: AFP)
    Public health officials hope it will convince more unvaccinated Americans that Pfizer's shot is safe and effective. Vaccine hesitancy among some Americans has hindered the United States' response to the novel coronavirus.
    "While millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated," said Janet Woodcock, the U.S. Food and Drug Administration's acting commissioner.
    2 View gallery
    מתחסנים בחיסון השלישי בירושלים
    מתחסנים בחיסון השלישי בירושלים
    A woman receiving the third jab of the COVID vaccine in Jerusalem
    (Photo: Reuters)
    Roughly 51% of Americans have been fully vaccinated so far, even as a recent surge of infections spurred by the contagious Delta variant ravages parts of the country with low vaccination rates.
    Comments
    The commenter agrees to the privacy policy of Ynet News and agrees not to submit comments that violate the terms of use, including incitement, libel and expressions that exceed the accepted norms of freedom of speech.
    ""